Like Gilead, AbbVie gets its tentacles into pact with Tentarix

The octopi at Tentarix Biotherapeutics are celebrating this morning.

AbbVie plans to pay $64 million upfront for two programs out of the San Diego biotech’s so-called Tentacles platform, spread across one target in oncology and the other in immunology, the drug developers said Thursday. If the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks